Erythroblast appearance associated with natalizumab

Area of Science:

• Hematology
• Neurology
• Immunology

Background:

• Natalizumab (NTZ) is a therapeutic antibody used for multiple sclerosis.
• The adverse effects of NTZ are well-documented, but erythroblast appearance in peripheral blood is not widely recognized.
• The underlying mechanisms and clinical course of NTZ-induced erythroblastosis are unclear.

Observation:

• This report details two cases of multiple sclerosis patients experiencing erythroblast appearance in peripheral blood following natalizumab administration.
• Erythroblasts were observed post-NTZ treatment, but their counts remained stable, and NTZ therapy was continued.
• No immediate adverse events necessitated NTZ discontinuation in these cases.

Findings:

• Natalizumab may inhibit erythroblastic island formation, a crucial process in red blood cell maturation, potentially mediated by VLA-4.
• The appearance of erythroblasts in peripheral blood during NTZ therapy is a transient phenomenon in some patients.
• The study suggests a link between natalizumab and the presence of immature red blood cells.

Implications:

• Clinicians should be aware of erythroblast appearance as a possible, though not alarming, side effect of natalizumab.
• Careful monitoring for anemia is recommended in patients receiving natalizumab, even with stable erythroblast counts.
• Further research is warranted to fully elucidate the VLA-4 inhibition mechanism and long-term implications of NTZ-associated erythroblastosis.